Mayflower Financial Advisors LLC Sells 318 Shares of Johnson & Johnson $JNJ

Mayflower Financial Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 2.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,959 shares of the company’s stock after selling 318 shares during the quarter. Mayflower Financial Advisors LLC’s holdings in Johnson & Johnson were worth $2,285,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Wealth Group Ltd. acquired a new stake in Johnson & Johnson during the first quarter worth approximately $218,000. Cornerstone Advisors Asset Management LLC grew its position in Johnson & Johnson by 11.8% during the first quarter. Cornerstone Advisors Asset Management LLC now owns 3,327 shares of the company’s stock worth $552,000 after buying an additional 352 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Johnson & Johnson by 0.9% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,044,313 shares of the company’s stock worth $1,002,389,000 after acquiring an additional 52,961 shares during the period. Finally, Little House Capital LLC lifted its position in shares of Johnson & Johnson by 53.5% during the 1st quarter. Little House Capital LLC now owns 28,711 shares of the company’s stock valued at $4,761,000 after acquiring an additional 10,007 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 1.8%

Shares of JNJ stock opened at $186.94 on Wednesday. The stock’s fifty day moving average price is $182.72 and its two-hundred day moving average price is $166.92. The company has a market cap of $450.40 billion, a PE ratio of 18.04, a P/E/G ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on JNJ shares. Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. The Goldman Sachs Group boosted their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Citigroup increased their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, October 15th. Finally, Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.